Ignite Creation Date:
2024-07-17 @ 10:53 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06464055
Status:
RECRUITING
Last Update Posted:
2024-06-18
First Post:
2024-06-07
Brief Title:
A Study of GQ1010 in Subjects With Advanced Solid Tumors
Sponsor:
GeneQuantum Healthcare Suzhou Co Ltd
Organization:
GeneQuantum Healthcare Suzhou Co Ltd
Study Overview
Official Title:
A Phase III Multicenter Open-Label Dose-Escalation and Extension Study of GQ1010an Anti-Trop2 ADC in Subjects With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label phase III study to evaluate the safety tolerability pharmacokinetics and immunogenicity of GQ1010 and preliminary anti-tumor efficacy in advanced malignant solid tumor subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None